The understanding of molecular mechanisms that underlie myofibroblastic transdifferentiation (MTD) of hepatic stellate cells (HSC), is a prerequisite for development of new therapeutic modalities for alcoholic liver cinliosis. We have approached this goal from a unique standpoint of cell fate regulation of pluripotent mesenchymal cells. In this end, we discovered "adipogenic regulation" is essential for HSC quiescence and loss of this regulation results in MTD. As such, restoration ofthe expression of PPAR?, the master regulator of adipogenesis in MFB achieves a phenotypic reversal of the cells to quiescent HSC, and this effect is completely abrogated by co-transduction of a dominant negative mutant of PPAR?. In search for the mechanisms of PPAR? repression in MTD, an international collaboration by Tsukamoto and Mann laboratories disclosed major contributions of two epigenetic regulators: the methyl CpG binding protein MeCP2 which causes HP1a recmitment to methylated H3K9 at PPAR? promoter;and the polycomb repressive complex 2 (PRC2) methyltransferase EZH2 which di- and tri-methylate H3K27 as another mechanism of powerful gene silencing. We also demonstrates a loss ofthe negative control with miR132 as a novel mechanism of MeCP2 induction which in turn positively regulates the expression of EZH2 in MTD. The proposed collaborative research is aimed at extending these ground-breaking findings on epigenetic regulation of MTD shown in culture-activated HSC, to MTD in alcoholic liver fibrogenesis. Toward this goal, the following specific aims will be pursued: 1) to determine whether MeCP2 and EZH2 mediated epigenetic mechanisms are evident in activated HSC/MFB isolated from the mouse model of alcoholic liver fibrosis;2) to determine whether MeCP2 knockout or a EZH2 inhibitor specifically targeted to activated HSC/MFB ameliorates alcoholic liver fibrosis;3) to validate MeCP2 and EZH2 mediated epigenetic regulation in activated HSC/MFB in alcoholic liver fibrosis in man. We believe that the proposed study will uncover novel mechanisms of alcoholic liver fibrosis and important therapeutic targets for the disease. PUBLIC HELATH

Public Health Relevance

The proposed international collaboration will disclose new information conceming how alcohol-induced cirrhosis of the liver develops and will test novel therapeutic approaches for the disease in animal models. It is our long-term goal that such treatment options will be made available for patients suffering from cirrhosis.

National Institute of Health (NIH)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Biomedical Research Review Subcommittee (AA)
Program Officer
Gao, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Schools of Medicine
Los Angeles
United States
Zip Code
Lazaro, Raul; Wu, Raymond; Lee, Sunyoung et al. (2015) Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology 61:129-40
Wilson, Caroline L; Mann, Jelena; Walsh, Meagan et al. (2014) Quiescent hepatic stellate cells functionally contribute to the hepatic innate immune response via TLR3. PLoS One 9:e83391
Mann, Derek A (2014) Epigenetics in liver disease. Hepatology 60:1418-25
Yang, Melissa D; Chiang, Yi-Ming; Higashiyama, Reiichi et al. (2012) Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor ? in hepatic stellate cells for their antifibrotic effect. Hepatology 55:1271-81
Zhu, Nian-Ling; Asahina, Kinji; Wang, Jiaohong et al. (2012) Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration. J Biol Chem 287:10355-67
Ueno, Akiko; Lazaro, Raul; Wang, Ping-Yen et al. (2012) Mouse intragastric infusion (iG) model. Nat Protoc 7:771-81
Tsukamoto, Hidekazu; Zhu, Nian-Ling; Wang, Jiaohong et al. (2012) Morphogens and hepatic stellate cell fate regulation in chronic liver disease. J Gastroenterol Hepatol 27 Suppl 2:94-8